Your browser doesn't support javascript.
loading
CAR-T cell-derived exosomes: a new perspective for cancer therapy.
Sani, Farnaz; Shojaei, Shabnam; Tabatabaei, Seyed Amirhossein; Khorraminejad-Shirazi, Mohammadhossein; Latifi, Mona; Sani, Mahsa; Azarpira, Negar.
Afiliación
  • Sani F; Shiraz Institute for Stem Cell & Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Shojaei S; School of Medicine, Shiraz Shiraz University of Medical Sciences, Shiraz, Iran.
  • Tabatabaei SA; School of Medicine, Shiraz Shiraz University of Medical Sciences, Shiraz, Iran.
  • Khorraminejad-Shirazi M; Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Latifi M; Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Sani M; Department of Pathology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Azarpira N; Department of Physiological Science, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, USA.
Stem Cell Res Ther ; 15(1): 174, 2024 Jun 18.
Article en En | MEDLINE | ID: mdl-38886844
ABSTRACT
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alternative to CAR-T cells that may overcome some limitations. Exosomes are small vesicles released by cells and can carry a variety of molecules, including proteins, RNA, and DNA. They play an important role in intercellular communication and can be used to deliver therapeutic agents to cancer cells. The application of CAR-T cell-derived exosomes could make CAR-T cell therapy more clinically controllable and effective. Exosomes are cell-free, which means that they are less likely to cause adverse reactions than CAR-T cells. The combination of CAR-T cells and exosomes may be a more effective way to treat cancer than either therapy alone. Exosomes can deliver therapeutic agents to cancer cells where CAR-T cells cannot reach. The appropriate application of both cellular and exosomal platforms could make CAR-T cell therapy a more practicable treatment for cancer. This combination therapy could offer a safe and effective way to treat a variety of cancers.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Exosomas / Receptores Quiméricos de Antígenos / Neoplasias Límite: Animals / Humans Idioma: En Revista: Stem Cell Res Ther Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Exosomas / Receptores Quiméricos de Antígenos / Neoplasias Límite: Animals / Humans Idioma: En Revista: Stem Cell Res Ther Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido